AJMC February 25, 2022
A webinar by the National Cancer Treatment Alliance discussed current use and diagnostic/therapeutic benefits of comprehensive genomic profiling in oncology, as well as recommendations for employers and benefit consultants considering biomarker testing.
With US spending on oncology care having doubled since 2013, a webinar by the National Cancer Treatment Alliance, an initiative of the Community Oncology Alliance (COA), discussed how employers can leverage biomarker testing to avoid unnecessary treatment costs and eliminate waste.
Frederick Schnell, MD, FACP, medical director of COA, began the webinar, “What Employers Need to Know About Biomarker Testing,” by highlighting how 64% of the growth in oncology care spending is attributable to the launch of new medicines. Accounting for 12% of employer health care spend, cancer...
Today's Sponsors
Today's Sponsor